Covishield &Sputnik V

 

Covishield &

Sputnik V

Covishield is the Indian version of the AstraZeneca/Oxford vaccine, produced by the Serum Institute of India.

  • Type: Viral vector vaccine, which uses a modified version of a common cold virus (adenovirus) to deliver instructions to cells to produce a harmless spike protein of the SARS-CoV-2 virus.
  • Efficacy: Clinical trials have shown it to be effective at preventing symptomatic COVID-19, with efficacy rates around 70-90% after two doses.
  • Dosing Schedule: Typically administered in two doses, with the second dose given 4 to 12 weeks after the first.
  • Storage: Can be stored at refrigerator temperatures (2-8°C), facilitating easier distribution.

Sputnik V

Sputnik V is a viral vector vaccine developed by the Gamaleya Research Institute in Russia. 

  • Type: Also a viral vector vaccine, it uses two different adenoviruses (Ad26 and Ad5) for the two doses, which helps boost the immune response.
  • Efficacy: Clinical trials indicated an efficacy rate of about 91.6% in preventing symptomatic COVID-19.
  • Dosing Schedule: Administered in two doses, with the second dose usually given 21 days after the first.
  • Storage: Can be stored at -18°C, which allows for wider distribution, especially in resource-limited settings.

Comments

Popular posts from this blog

Biochemistry plays in space exploration

Kidney function tests

Mpox